Dosage of estradiol, bone and body composition in Turner syndrome: a 5-year randomized controlled clinical trial.

Objective: Reduced bone mineral density (BMD) is seen in Turner syndrome (TS) with an increased risk of fractures, and body composition is characterized by increased body fat and decreased lean body mass. To evaluate the effect of two different doses of oral 17B-estradiol in young TS women on bone mineral density (BMD), biochemical markers of bone turnover and body composition with the hypothesis of a positive effect of the higher dose.

Design: A double-blind 5-year randomized controlled clinical trial.

Normal tempo of bone formation in Turner syndrome despite signs of accelerated bone resorption.

Aims: To evaluate area bone mineral density (aBMD) and volumetric BMD (vBMD) by dual-energy X-ray absorptiometry, and relations to bone markers and hormones in adolescent women with Turner syndrome (TS).

Methods: Cross-sectional study in TS patients (n = 37, 16.7 ± 3.